Literature DB >> 9700703

Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis.

J De Keyser1, C Zwanikken, M Boon.   

Abstract

Despite reports that influenza vaccination appears to be safe in multiple sclerosis there is uncertainty which patients may benefit from it. By using a questionnaire we compared the effects of influenza illness (1995-1996 season) and influenza vaccination (autumn of 1996) on neurologic symptoms in patients with multiple sclerosis registered in the Groningen Multiple Sclerosis Data Bank. No clinically relevant effects were reported in 53 patients with primary progressive multiple sclerosis, either following vaccination or the illness. In a group of 180 patients with relapsing multiple sclerosis, an exacerbation occurred within the following 6 weeks in 33% after influenza illness, whereas it occurred in only 5% after vaccination. The exacerbation rate following influenza illness was significantly higher regardless of whether patients were essentially restricted to wheelchair or not. Because of a substantial greater risk of relapse after influenza illness than after vaccination, annual influenza vaccination should be offered routinely to all patients with relapsing multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9700703     DOI: 10.1016/s0022-510x(98)00139-7

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  26 in total

Review 1.  Vaccination against infection in patients with multiple sclerosis.

Authors:  Micha Loebermann; Alexander Winkelmann; Hans-Peter Hartung; Hartmut Hengel; Emil C Reisinger; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2012-01-24       Impact factor: 42.937

Review 2.  [Vaccination and multiple sclerosis].

Authors:  M Löbermann; A Winkelmann; E C Reisinger; U K Zettl
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

3. 

Authors:  Norbert Wagner; Frauke Assmus; Gabriele Arendt; Erika Baum; Ulrich Baumann; Christian Bogdan; Gerd Burchard; Dirk Föll; Edeltraut Garbe; Jane Hecht; Ulf Müller-Ladner; Tim Niehues; Klaus Überla; Sabine Vygen-Bonnet; Thomas Weinke; Miriam Wiese-Posselt; Michael Wojcinski; Fred Zepp
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2019-04       Impact factor: 1.513

Review 4.  Vaccines in Multiple Sclerosis.

Authors:  Eric M L Williamson; Salim Chahin; Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

5.  Influenza infection triggers disease in a genetic model of experimental autoimmune encephalomyelitis.

Authors:  Stephen Blackmore; Jessica Hernandez; Michal Juda; Emily Ryder; Gregory G Freund; Rodney W Johnson; Andrew J Steelman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-10       Impact factor: 11.205

Review 6.  Vaccination recommendations for adult patients with rheumatic diseases.

Authors:  Mine Durusu Tanrıöver; Servet Akar; Nuran Türkçapar; Ömer Karadağ; İhsan Ertenli; Sedat Kiraz
Journal:  Eur J Rheumatol       Date:  2015-10-28

Review 7.  Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner.

Authors:  Celia Oreja-Guevara; Heinz Wiendl; Bernd C Kieseier; Laura Airas
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

8.  Targeting myelin proteolipid protein to the MHC class I pathway by ubiquitination modulates the course of experimental autoimmune encephalomyelitis.

Authors:  Diethilde J Theil; Jane E Libbey; Fernando Rodriguez; J Lindsay Whitton; Ikuo Tsunoda; Tobias J Derfuss; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2008-11-15       Impact factor: 3.478

9.  Virus-induced CD8+ T cells accelerate the onset of experimental autoimmune encephalomyelitis: implications for how viral infections might trigger multiple sclerosis exacerbations.

Authors:  Emily K Rainey-Barger; Pennelope K Blakely; Amanda K Huber; Benjamin M Segal; David N Irani
Journal:  J Neuroimmunol       Date:  2013-04-18       Impact factor: 3.478

Review 10.  Potential triggers of MS.

Authors:  Jane E Libbey; Robert S Fujinami
Journal:  Results Probl Cell Differ       Date:  2010
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.